BRAINBox Solutions is developing the first AI-enabled, multi-modality approach for the diagnosis and prognosis of Mild Traumatic Brain Injury, commonly referred to as a concussion. The company seeks to establish a clinical best-practice standard for the diagnosis and prognosis of concussion. The product incorporates a panel of proprietary, patented blood biomarkers that can be read in a few moments on a point-of-care instrument or using standard laboratory systems, as well as neurocognitive testing, to provide a single-system score that measures the severity of the injury and guide treatment. The company is led by key physician and scientific thought leaders in the field and an experienced, clinically focused management team.
| Date | Amount | Type | Investors | Valuation |
|---|---|---|---|---|
| 12/09/20 | $23,000,000 | Series A |
Astia Angels BioVentures Investors  Genoa Ventures Kevin Love Pharmakon Holdings Seed Funds Tauber Foundation Virginia Tech Carilion Innovation | undisclosed |
